What is Rhythm Pharmaceuticals Inc. Annual Revenue?

Rhythm Pharmaceuticals Inc. Annual Revenue rose 68.06%, in the last year to $130.13 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Rhythm Pharmaceuticals Inc. Annual Net Profit?

Rhythm Pharmaceuticals Inc. Annual Net Profit fell 41.11% in the last year to $260.6 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Rhythm Pharmaceuticals Inc. Price to Earning Ratio?

Rhythm Pharmaceuticals Inc. Price to Earning Ratio is -14.61, which is negative.

What is Rhythm Pharmaceuticals Inc. Stock Price?

Rhythm Pharmaceuticals Inc. Stock Price rose 58.43% and outperformed its sector by 50.07% in the past year.

What is Rhythm Pharmaceuticals Inc. Quarterly Revenue?

Rhythm Pharmaceuticals Inc. Quarterly Revenue rose 72.61% YoY to $41.83 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Rhythm Pharmaceuticals Inc. Quarterly Net profit?

Rhythm Pharmaceuticals Inc. Quarterly Net profit fell 3.98% YoY to $43.29 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Rhythm Pharmaceuticals Inc. Debt to Equity Ratio?

Rhythm Pharmaceuticals Inc. Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Rhythm Pharmaceuticals Inc. Return on Equity(ROE)?

Rhythm Pharmaceuticals Inc. Return on Equity(ROE) for the last financial year was -276.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Rhythm Pharmaceuticals Inc. Mutual Fund Holding?

Rhythm Pharmaceuticals Inc. Mutual Fund Holding increased by 1.68% in the last quarter to 61.07.

What is Rhythm Pharmaceuticals Inc. Promoter Share Holding?

Rhythm Pharmaceuticals Inc. Promoter Share Holding increased by 0.16% in the most recent quarter to 0.94%.

What is Rhythm Pharmaceuticals Inc. Interest Coverage Ratio?

Rhythm Pharmaceuticals Inc. Interest Coverage Ratio is -11.63, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Rhythm Pharmaceuticals Inc. Institutional Holding?

Rhythm Pharmaceuticals Inc. Institutional Holding increased by 0.03% in the last quarter to 99.81.

How is the Rhythm Pharmaceuticals Inc. today?

The Rhythm Pharmaceuticals Inc. today is trading in the down by -0.43% at 60.22.

How has Rhythm Pharmaceuticals Inc. performed historically?

The Rhythm Pharmaceuticals Inc. is currently trading down -0.43% on an intraday basis in the past week the index rose 0.13%. The index has been up 4.69% in the past quarter and rose 58.43% in the past year. You can view this in the overview section.

Rhythm Pharmaceuticals Inc. XNAS: RYTM

Rhythm Pharmaceuticals Inc. Live Share Price Today, Share Analysis and Chart

Name: Rhythm Pharmaceuticals Inc.: Is Infosys Ltd. worth buying?
Item: Rhythm Pharmaceuticals Inc.
Rating: 1.676791625
Author: Trendlyne DVM scores

Momentum Trap

Download real time

60.22 -0.26 (-0.43%)

71.23% Gain from 52W Low

469.2K XNAS Volume

XNAS 22 Apr, 2025 2:12 PM (EDT)

Rhythm Pharmaceuticals Inc. Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	3,807.3
PE TTM Negative PE TTM Unavailable in chosen country	-14.6
PEG TTM High in industry Unavailable in chosen country	0.4
Price to Book High in industry Unavailable in chosen country	175.2
Institutional holding current Qtr % High in industry Unavailable in chosen country	99.8
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	72.6
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	68.1
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-4
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-41.1
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-98.6
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-204
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	5.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-276.3
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-73

All financials are in USD Million and price data in USD

Low Financial Strength

33.3 / 100

Expensive Valuation

3.7 / 100

Technically Moderately Bullish

63.8 / 100

Momentum Trap These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked. View Similar Embed DVM

1Yr Price target upside is 30%

12 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Rhythm Pharmaceuticals Inc. Stock Price Analysis

Day Price Range -0.4% 1 Day return Unavailable in chosen country	60.2 (LTP) 6062.3 LowHigh
Week Price Range 0.1% 1 Week return Unavailable in chosen country	60.2 (LTP) 59.562.8 LowHigh
Month Price Range 15.7% 1 Month return Unavailable in chosen country	60.2 (LTP) 45.963.1 LowHigh
52 Week Price Range 58.4% 1 Year return Unavailable in chosen country	60.2 (LTP) 35.268.6 LowHigh

View full Share Price History

Rhythm Pharmaceuticals Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Consensus Recommendation

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Rhythm Pharmaceuticals Inc. Stock Analysis

Rhythm Pharmaceuticals Inc. stock analysis with key metrics, changes, and trends.

Rhythm Pharmaceuticals Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$130.13 M	68.06%	positive	Annual Revenue rose 68.06%, in the last year to $130.13 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$260.6 M	41.11%	negative	Annual Net Profit fell 41.11% in the last year to $260.6 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-14.61	-	negative	Price to Earning Ratio is -14.61, which is negative.
Stock Price	$60.22	58.43%	positive	Stock Price rose 58.43% and outperformed its sector by 50.07% in the past year.
Quarterly Revenue	$41.83 M	72.61%	positive	Quarterly Revenue rose 72.61% YoY to $41.83 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$43.29 M	3.98%	negative	Quarterly Net profit fell 3.98% YoY to $43.29 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	0.18	-	positive	Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-276.33 %	-276.33%	negative	Return on Equity(ROE) for the last financial year was -276.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	61.07 %	1.68%	positive	Mutual Fund Holding increased by 1.68% in the last quarter to 61.07.
Promoter Share Holding	0.94 %	0.16%	positive	Promoter Share Holding increased by 0.16% in the most recent quarter to 0.94%.
Interest Coverage Ratio	-11.63	-	negative	Interest Coverage Ratio is -11.63, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	99.81 %	0.03%	positive	Institutional Holding increased by 0.03% in the last quarter to 99.81.

VIEW LESS

Loading data..

Rhythm Pharmaceuticals Inc. - Company Profile

What does Rhythm Pharmaceuticals Inc. do?

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Gross Remuneration

2024

Gross Remuneration

Year

Rhythm Pharmaceuticals Inc. Live Share Price Today, Share Analysis and Chart

71.23% Gain from 52W Low

Rhythm Pharmaceuticals Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Rhythm Pharmaceuticals Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Rhythm Pharmaceuticals Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Consensus Recommendation

Rhythm Pharmaceuticals Inc. Stock Analysis

Rhythm Pharmaceuticals Inc. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 68.06%, in the last year to $130.13 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit fell 41.11% in the last year to $260.6 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -14.61, which is negative.

Stock Price rose 58.43% and outperformed its sector by 50.07% in the past year.

Quarterly Revenue rose 72.61% YoY to $41.83 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit fell 3.98% YoY to $43.29 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -276.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 1.68% in the last quarter to 61.07.

Promoter Share Holding increased by 0.16% in the most recent quarter to 0.94%.

Interest Coverage Ratio is -11.63, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.03% in the last quarter to 99.81.

Rhythm Pharmaceuticals Inc. - Company Profile

What does Rhythm Pharmaceuticals Inc. do?

Rhythm Pharmaceuticals Inc. Management structure

Dr. David P. Meeker,M.D.

Chairman of the Board, President and Chief Executive Officer

Mr. Hunter C. Smith

Chief Financial Officer and Treasurer

Mr. Christopher P. German

Director, Corporate Controller and Principal Accounting Officer

Rhythm Pharmaceuticals Inc. Board of directors

Mr. Christophe R. Jean

Independent Director

Dr. David P. Meeker,M.D.

Chairman of the Board, President and Chief Executi

Mr. Edward T. Mathers

Lead Independent Director

Mr. David W.J. McGirr, M.B.A.

Independent Director

Ms. Jennifer L. Good

Independent Director

Dr. Camille L. Bedrosian,M.D.

Independent Director

Rhythm Pharmaceuticals Inc. FAQ

How is Rhythm Pharmaceuticals Inc. today?

Rhythm Pharmaceuticals Inc. today is trading in the red, and is down by -0.43% at 60.22.

How has Rhythm Pharmaceuticals Inc. performed historically?

Rhythm Pharmaceuticals Inc. is currently trading down -0.43% on an intraday basis. In the past week the stock rose 0.13%. stock has been up 4.69% in the past quarter and rose 58.43% in the past year. You can view this in the overview section.